Long-Term Effects of Antiviral Treatment for Hepatitis C. Ann Intern Med. 2005;142:I-51. doi: 10.7326/0003-4819-142-2-200501180-00004
Download citation file:
Published: Ann Intern Med. 2005;142(2):I-51.
Hepatitis C is inflammation of the liver caused by hepatitis C virus (HCV). HCV is transmitted primarily by blood-to-blood contact through needlestick accidents, intravenous drug use, body piercing, and tattooing. Most people do not rid their body of HCV on their own. More than 80% keep the virus in their blood for longer than 6 months and develop chronic hepatitis C.
Chronic hepatitis C progresses slowly over 10 to 30 years. It causes inflammation and severe scarring of the liver (cirrhosis). If untreated, it can lead to liver failure and liver cancer. Treatment with antiviral drugs, such as interferon, clears HCV from the blood and helps prevent some liver damage. Few studies, however, show whether treatment can prevent liver cancer in patients who already have severe scarring or cirrhosis.
To see whether antiviral therapy prevents liver tumors and improves long-term survival in patients with chronic hepatitis C and cirrhosis.
345 adults with chronic hepatitis C and cirrhosis: 74 had declined to receive antiviral treatment and 271 had received interferon injections.
In the early 1990s, the researchers conducted 2 trials of interferon therapy in patients with chronic hepatitis C and liver scarring. Patients in the trials received interferon injections 3 times a week for 26 to 88 weeks. For several years, the researchers followed these patients, as well as patients who declined antiviral therapy (median follow-up, 6.8 years). Every few months, the researchers tested the patients' blood for HCV and signs of liver inflammation, and they did liver ultrasonography to check for tumors. Additional tests, such as computed tomography and liver biopsies, were done to see whether any tumors were cancer. The researchers then compared outcomes among people who had and had not received antiviral treatment.
Liver cancer occurred in 47% of the patients who declined treatment compared with 31% of those treated with interferon. In addition, more patients who declined treatment died than did those who got interferon (32% vs. 17%).
The study was not a randomized, controlled trial. Factors other than the interferon treatment might have contributed to the differences between groups. The study did not assess effects of different types of treatments for hepatitis C.
Antiviral treatment with interferon might prevent liver cancer and improve survival in some patients with chronic hepatitis C and cirrhosis.
The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.
Gastroenterology/Hepatology, Infectious Disease, Liver Disease.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only